A monoamine oxidase-B inhibitor, MD 780236, metabolized essentially by the A form of the enzyme in the rat.
In-vivo studies on the metabolism of [14C]MD 780236 a short-acting selective type B MAO inhibitor in the rat showed the acid to be the major metabolite in plasma and urine, whereas it was minor in brain, where the alcohol was the major metabolite. Pretreatment with SKF 525-A did not modify the metabolite profile in brain, but benserazide decreased the alcohol. Pretreatment with (-)-selegiline had no effect, but clorgyline or clorgyline with (-)-selegiline significantly decreased the alcohol and increased the primary amine metabolite in brain. In-vivo results suggest that MAO-A is the enzyme responsible for the metabolism of MD 780236. This was confirmed by in-vitro studies. Rat brain homogenates extensively metabolized the drug, with the aldehyde being the major metabolite formed (28% of the total radioactivity in the incubation mixture after 60 min incubation). The acid (12%) was more important than the alcohol (4%) in-vitro. The addition of all metabolites originating from possible MAO activity gave 46% when the incubation was carried out at pH 7.4 and 82% at pH 8.8. The presence of NADPH or NAD+ did not alter the relative amounts of metabolites formed. Total metabolites originating from MAO activity in the presence of (-)-selegiline accounted for 40% of total radioactivity, whereas in the presence of clorgyline they accounted for 8% and in the presence of both clorgyline and (-)-selegiline they were reduced to 3%, compared with 45% in controls. As a further proof of the importance of MAO-A in the metabolism of MD 780236, rats were pretreated with clorgyline 1 h before the drug and MAO-B inhibition measured at different times ex-vivo in brain and liver. The short-lasting phase of inhibition of MAO-B disappeared after pretreatment with clorgyline, and inhibition at 24 h was as high as that at 1 h. These results demonstrate the importance of the A form of MAO for the metabolism of MD 780236.